Mechanistically, the activation of CD8+ T cells by TCR signalling leads to the upregulation of RIG-I, which in turn inhibits the AKT/glycolysis signalling pathway, negatively regulating anti-tumour function. The gene discussed is CD8A; the disease is neoplasm.